Interested?
If you would like more information on our NT-proBNP assay, share your details below and a Roche representative will reach out shortly.
Key takeaways
- Insight into guideline recommendations for NT-proBNP in heart failure evaluation and management
- Practical understanding of how NT-proBNP supports earlier diagnosis and risk stratification in high-risk and comorbid patients
- Strategies for integrating NT-proBNP testing with standard assessments to enhance patient monitoring, management, and resource optimization
Catching Heart Failure Early: The Power of NT-proBNP in Clinical Practice
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Catching Heart Failure Early: The Power of NT-proBNP in Clinical Practice* (60:00)
Heart failure affects millions of patients, yet early diagnosis remains a persistent challenge. In this session, hear from Neil Skolnik, MD; Ileana Piña, MD; and Nishant Shah, MD as they review the clinical evidence behind NT-proBNP and demonstrate how this guideline-recommended biomarker is being applied in real-world care to support more informed, timely decision-making.
*Speaker fees and honoraria for this presentation were provided by Roche Diagnostics
Section 1: The role of NT-proBNP testing
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
The role of NT-proBNP testing (8:07)
Overview of the role of natriuretic peptides (NT-proBNP) testing in early heart failure detection and guideline recommendations to evaluate non-specific dyspnea.
Section 2: Early diagnosis of heart failure
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Early diagnosis of heart failure (7:20)
Explains how team-based care allows clinicians to detect subclinical (Stage B) HF before symptomatic stages.
Section 3: Risks and evidence
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Risks and evidence (10:37)
Links hypertension, diabetes, and obesity with heart failure. Real world evidence showing actionable improvement in HF outcomes.
Section 4: Evaluation and management
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Evaulation and management (6:47)
Lays out a step-by-step algorithm to shift the diagnostic approach and offering therapeutic alternatives.
Section 5: Key points
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Key points (2:58)
The shift from reactive care to early, proactive heart failure detection.
Section 6: Cases
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Live cases (12:38)
2 cases addressing subclinical symptoms, risk factors and actions taken.
Section 7: Q&A Session
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Q&A session (8:57)
Attendees ask key questions about the clinical utility of NT-proBNP.
Contact Us
Do you have questions about our NT-proBNP assay? We’re here to help. Contact a Roche representative in your region.
